Trials / Approved For Marketing
Approved For MarketingNCT02355054
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to provide clinical access to PET/CT and PET/MRI with C-11 choline for evaluation of men with biochemically recurrent prostate cancer while awaiting approval of the Washington University Abbreviated New Drug Application for C-11 choline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C-11 Choline PET Imaging | Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner |
Timeline
- First posted
- 2015-02-04
- Last updated
- 2017-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02355054. Inclusion in this directory is not an endorsement.